Phase I and II trial to evaluate the use of anti‐carcinoembryonic antigen radioimmunotherapy (anti‐CEA RAIT), wherein a bi‐labeled antibody (bsMAb) targets NSCLC tumors and delivers radiationTwo specific goals of determining the optimal TF2 protein dose for the radiation delivery (IMP‐288‐Lutetium) and the maximum tolerated dose of the imaging (IMP‐288‐Indium) and treatment radiationWere able to successfully demonstrate low immunogenicity and low toxicity of the anti‐CEA RAIT, and the potential for the anti‐CEA RAIT to be utilized as an anti‐tumor therapeutic121. This evidence concerns the gene CEACAM5 and non-small cell lung carcinoma.